We are proud to announce that Carles and Xavi co-founded Oniria Therapeutics, a new spin-off launched on March 2022. The Vall d’Hebron Institute of Oncology (VHIO), Universidad de Barcelona (UB), and the ICREA Catalan Institution for Research and Advanced Studies, have joined forces to create it. Oniria aims to modulate cell dormancy to overcome cancer persistance with novel therapeutic approaches.
You can read the entire post here.